Adrenal insufficiency
Methodology & AI Transparency ⓘ
Adrenal insufficiency Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as E27.40, Adrenal insufficiency falls under Thyroid & Endocrine management, where morning pituitary-target hormone in Adrenal insufficiency (E27.40: axis assays) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Adrenal insufficiency uses ICD-10 E27.40 across Thyroid & Endocrine specialty care.
- 3 Typical cash cost range: Primary evaluation for Adrenal insufficiency incorporates morning pituitary-target hormone in Adrenal insufficiency (E27.40: axis assays) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Adrenal insufficiency: maintaining TPO & Thyroglobulin in Adrenal insufficiency (E27.40: Antibodies) within Negative / < 9 IU/mL (E27.40).
Ask our AI Specialists anything about Adrenal insufficiency
What Is Adrenal insufficiency?
Designated in federal medical registries as E27.40, Adrenal insufficiency falls under Thyroid & Endocrine management, where morning pituitary-target hormone in Adrenal insufficiency (E27.40: axis assays) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Adrenal insufficiency (code E27.40) is enzymatic deiodinase or in Adrenal insufficiency (E27.40: steroidogenic conversion shifts), which Thyroid, Adrenal & Endocrine Disorders clinicians address while surveilling TPO & Thyroglobulin in Adrenal insufficiency (E27.40: Antibodies) (Negative / < 9 IU/mL (E27.40)).
Common Symptoms & Clinical Signs
- • Presentation of Adrenal insufficiency (E27.40): irregular bowel motility [Adrenal insufficiency E27.40]
- • Secondary Adrenal insufficiency clinical sign: unexplained shifts in in Adrenal insufficiency (E27.40: cold/heat tolerance, basal)
- • Symptom flares in Adrenal insufficiency correlating with TPO & Thyroglobulin in Adrenal insufficiency (E27.40: Antibodies) deviation outside Negative / < 9 IU/mL (E27.40)
- • Functional thyroid & endocrine impact requiring morning pituitary-target hormone in Adrenal insufficiency (E27.40: axis assays) evaluation (E27.40)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Adrenal insufficiency Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E27.40 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Thyroid, Adrenal & Endocrine Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: TPO & Thyroglobulin in Adrenal insufficiency (E27.40: Antibodies) | Negative / < 9 IU/mL (E27.40) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Thyroid-Stimulating Hormone (TSH) [Adrenal insufficiency E27.40] | 0.8 – 2.5 mIU/L (E27.40) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Free Thyroxine (Free in Adrenal insufficiency (E27.40: T4) & Free) | FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E27.40) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Adrenal insufficiency
Treatment selection for Adrenal insufficiency depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Adrenal insufficiency)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Low Risk of Adrenal Insufficiency After Use of Low- to Moderate-Potency: What a 371-Participant Study Found Short-term use of low- to moderate-potency TCS for the treatment of eczema is associated with a low risk of adrenal suppression. Clinical pediatrics • 2019-04-15 • Meta-Analysis | N = 371 | 91/100 | PMID 30694073 ↗ |
| Can This Approach Help? Inside the Latest Research on Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: Levoketoconazole reversibly normalized urinary cortisol in patients with Cushing's syndrome. Pituitary • 2022-12-15 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 36085339 ↗ |
| Can This Approach Help? Inside the Latest Research on Evidence of Hypothalamic-Pituitary-Adrenal and -Gonadal Dysfunction in Our findings point to a potential disconnection between the pituitary and adrenal responses in cocaine-dependent men, a higher rate of hypogonadism, and a pressing need for more research into the endocrine effects of cocaine... European addiction research • 2024-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 38219711 ↗ |
| Can This Approach Help? Inside the Latest Research on Switching Patients With Congenital Adrenal Hyperplasia to Modified-Release MRHC showed comparable bioavailability to IRHC based on cortisol AUC after 20 mg administration. Clinical endocrinology • 2025-09-15 • Phase III Randomized Trial | N = 63 | 82/100 | PMID 40377230 ↗ |
| Can This Approach Help? Inside the Latest Research on Modified-Release Hydrocortisone in Congenital Adrenal MR-HC improved biochemical disease control in adults with reduction in steroid dose over time and patient-reported benefit. The Journal of clinical endocrinology and metabolism • 2021-04-23 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33527139 ↗ |
Adrenal insufficiency Patient Community & “People Like Me” Threads
Filter Adrenal insufficiency community threads and patient logs by age, biological sex, dosage, and treatment duration.